Review



pmrfp lc3 rfp tagged lc3 dr tamotsu yoshimori  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Addgene inc pmrfp lc3 rfp tagged lc3 dr tamotsu yoshimori
    Pmrfp Lc3 Rfp Tagged Lc3 Dr Tamotsu Yoshimori, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 134 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pmrfp lc3 rfp tagged lc3 dr tamotsu yoshimori/product/Addgene inc
    Average 93 stars, based on 134 article reviews
    pmrfp lc3 rfp tagged lc3 dr tamotsu yoshimori - by Bioz Stars, 2026-05
    93/100 stars

    Images



    Similar Products

    94
    Bioss anti 296 rfp
    Anti 296 Rfp, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti 296 rfp/product/Bioss
    Average 94 stars, based on 1 article reviews
    anti 296 rfp - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    96
    Proteintech rfp tag
    Rfp Tag, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rfp tag/product/Proteintech
    Average 96 stars, based on 1 article reviews
    rfp tag - by Bioz Stars, 2026-05
    96/100 stars
      Buy from Supplier

    96
    Proteintech anti gfp 50430 2 ap proteintech anti rfp 5f8 proteintech anti hmgcr sc 271595 santa cruz anti cd45 a700 423112 biolegend anti itgam pe
    Anti Gfp 50430 2 Ap Proteintech Anti Rfp 5f8 Proteintech Anti Hmgcr Sc 271595 Santa Cruz Anti Cd45 A700 423112 Biolegend Anti Itgam Pe, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti gfp 50430 2 ap proteintech anti rfp 5f8 proteintech anti hmgcr sc 271595 santa cruz anti cd45 a700 423112 biolegend anti itgam pe/product/Proteintech
    Average 96 stars, based on 1 article reviews
    anti gfp 50430 2 ap proteintech anti rfp 5f8 proteintech anti hmgcr sc 271595 santa cruz anti cd45 a700 423112 biolegend anti itgam pe - by Bioz Stars, 2026-05
    96/100 stars
      Buy from Supplier

    90
    Abbkine Inc rfp-tag mouse mab (gfp tag mouse mab) antibody
    Rfp Tag Mouse Mab (Gfp Tag Mouse Mab) Antibody, supplied by Abbkine Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rfp-tag mouse mab (gfp tag mouse mab) antibody/product/Abbkine Inc
    Average 90 stars, based on 1 article reviews
    rfp-tag mouse mab (gfp tag mouse mab) antibody - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    93
    Addgene inc pmrfp lc3 rfp tagged lc3 dr tamotsu yoshimori
    Pmrfp Lc3 Rfp Tagged Lc3 Dr Tamotsu Yoshimori, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pmrfp lc3 rfp tagged lc3 dr tamotsu yoshimori/product/Addgene inc
    Average 93 stars, based on 1 article reviews
    pmrfp lc3 rfp tagged lc3 dr tamotsu yoshimori - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    90
    OriGene rfp-tagged rhob
    The ability of PDE11Ai’s to reverse PDE11A4 LLPS was unaffected by A) preventing phosphorylation at S163, or B) preventing phosphorylation of at S239. Although introducing the A499D mutation that stabilizes PDE11A4 homodimerization did not completely block the ability of C) BC11-38 and D) SMQ-02-57 to reduce PDE11A4 LLPS, E) it did reduce the effectiveness of PDE11Ai’s across 6 experiments. F) Further, the ability of the A499D mutant to increase PDE11A4 LLPS in this series was ∼3-fold greater in the inhibitor-treated vs. vehicle-treated cells. Next we assessed the therapeutic potential PDE11Ai’s by determining if they could reverse the increased PDE11A4 LLPS caused by G) the aging-related S117D/S124D mutant,H) staurosporine, or the overexpression of the trans-Golgi network proteins I) TGN-38 (a.k.a. TGOLN1) and J) <t>RhoB.</t> In each experiment, PDE11Ai’s completely blocked the effects of the pro-LLPS manipulations. Post hoc: *vs. vehicle, P=0.0145-0.0001; #vs. WT, mCherry, or 0 µM staurosporine, P=0.0465-0.0001.
    Rfp Tagged Rhob, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rfp-tagged rhob/product/OriGene
    Average 90 stars, based on 1 article reviews
    rfp-tagged rhob - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    90
    GenScript corporation rfp-tag primary antibody ref. a00682
    The ability of PDE11Ai’s to reverse PDE11A4 LLPS was unaffected by A) preventing phosphorylation at S163, or B) preventing phosphorylation of at S239. Although introducing the A499D mutation that stabilizes PDE11A4 homodimerization did not completely block the ability of C) BC11-38 and D) SMQ-02-57 to reduce PDE11A4 LLPS, E) it did reduce the effectiveness of PDE11Ai’s across 6 experiments. F) Further, the ability of the A499D mutant to increase PDE11A4 LLPS in this series was ∼3-fold greater in the inhibitor-treated vs. vehicle-treated cells. Next we assessed the therapeutic potential PDE11Ai’s by determining if they could reverse the increased PDE11A4 LLPS caused by G) the aging-related S117D/S124D mutant,H) staurosporine, or the overexpression of the trans-Golgi network proteins I) TGN-38 (a.k.a. TGOLN1) and J) <t>RhoB.</t> In each experiment, PDE11Ai’s completely blocked the effects of the pro-LLPS manipulations. Post hoc: *vs. vehicle, P=0.0145-0.0001; #vs. WT, mCherry, or 0 µM staurosporine, P=0.0465-0.0001.
    Rfp Tag Primary Antibody Ref. A00682, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rfp-tag primary antibody ref. a00682/product/GenScript corporation
    Average 90 stars, based on 1 article reviews
    rfp-tag primary antibody ref. a00682 - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    90
    GenScript corporation rfp-tag primary antibody genscript ref. a00682
    The ability of PDE11Ai’s to reverse PDE11A4 LLPS was unaffected by A) preventing phosphorylation at S163, or B) preventing phosphorylation of at S239. Although introducing the A499D mutation that stabilizes PDE11A4 homodimerization did not completely block the ability of C) BC11-38 and D) SMQ-02-57 to reduce PDE11A4 LLPS, E) it did reduce the effectiveness of PDE11Ai’s across 6 experiments. F) Further, the ability of the A499D mutant to increase PDE11A4 LLPS in this series was ∼3-fold greater in the inhibitor-treated vs. vehicle-treated cells. Next we assessed the therapeutic potential PDE11Ai’s by determining if they could reverse the increased PDE11A4 LLPS caused by G) the aging-related S117D/S124D mutant,H) staurosporine, or the overexpression of the trans-Golgi network proteins I) TGN-38 (a.k.a. TGOLN1) and J) <t>RhoB.</t> In each experiment, PDE11Ai’s completely blocked the effects of the pro-LLPS manipulations. Post hoc: *vs. vehicle, P=0.0145-0.0001; #vs. WT, mCherry, or 0 µM staurosporine, P=0.0465-0.0001.
    Rfp Tag Primary Antibody Genscript Ref. A00682, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rfp-tag primary antibody genscript ref. a00682/product/GenScript corporation
    Average 90 stars, based on 1 article reviews
    rfp-tag primary antibody genscript ref. a00682 - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    90
    Thermo Fisher rhodamine phalloidin fluorescently tagged with rfp
    The ability of PDE11Ai’s to reverse PDE11A4 LLPS was unaffected by A) preventing phosphorylation at S163, or B) preventing phosphorylation of at S239. Although introducing the A499D mutation that stabilizes PDE11A4 homodimerization did not completely block the ability of C) BC11-38 and D) SMQ-02-57 to reduce PDE11A4 LLPS, E) it did reduce the effectiveness of PDE11Ai’s across 6 experiments. F) Further, the ability of the A499D mutant to increase PDE11A4 LLPS in this series was ∼3-fold greater in the inhibitor-treated vs. vehicle-treated cells. Next we assessed the therapeutic potential PDE11Ai’s by determining if they could reverse the increased PDE11A4 LLPS caused by G) the aging-related S117D/S124D mutant,H) staurosporine, or the overexpression of the trans-Golgi network proteins I) TGN-38 (a.k.a. TGOLN1) and J) <t>RhoB.</t> In each experiment, PDE11Ai’s completely blocked the effects of the pro-LLPS manipulations. Post hoc: *vs. vehicle, P=0.0145-0.0001; #vs. WT, mCherry, or 0 µM staurosporine, P=0.0465-0.0001.
    Rhodamine Phalloidin Fluorescently Tagged With Rfp, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rhodamine phalloidin fluorescently tagged with rfp/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    rhodamine phalloidin fluorescently tagged with rfp - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    Image Search Results


    The ability of PDE11Ai’s to reverse PDE11A4 LLPS was unaffected by A) preventing phosphorylation at S163, or B) preventing phosphorylation of at S239. Although introducing the A499D mutation that stabilizes PDE11A4 homodimerization did not completely block the ability of C) BC11-38 and D) SMQ-02-57 to reduce PDE11A4 LLPS, E) it did reduce the effectiveness of PDE11Ai’s across 6 experiments. F) Further, the ability of the A499D mutant to increase PDE11A4 LLPS in this series was ∼3-fold greater in the inhibitor-treated vs. vehicle-treated cells. Next we assessed the therapeutic potential PDE11Ai’s by determining if they could reverse the increased PDE11A4 LLPS caused by G) the aging-related S117D/S124D mutant,H) staurosporine, or the overexpression of the trans-Golgi network proteins I) TGN-38 (a.k.a. TGOLN1) and J) RhoB. In each experiment, PDE11Ai’s completely blocked the effects of the pro-LLPS manipulations. Post hoc: *vs. vehicle, P=0.0145-0.0001; #vs. WT, mCherry, or 0 µM staurosporine, P=0.0465-0.0001.

    Journal: bioRxiv

    Article Title: Molecular mechanisms regulating PDE11A4 age-related liquid-liquid phase separation (LLPS) and its reversal by selective, potent and orally-available PDE11A4 small molecule inhibitors both in vitro and in vivo

    doi: 10.1101/2025.05.20.654583

    Figure Lengend Snippet: The ability of PDE11Ai’s to reverse PDE11A4 LLPS was unaffected by A) preventing phosphorylation at S163, or B) preventing phosphorylation of at S239. Although introducing the A499D mutation that stabilizes PDE11A4 homodimerization did not completely block the ability of C) BC11-38 and D) SMQ-02-57 to reduce PDE11A4 LLPS, E) it did reduce the effectiveness of PDE11Ai’s across 6 experiments. F) Further, the ability of the A499D mutant to increase PDE11A4 LLPS in this series was ∼3-fold greater in the inhibitor-treated vs. vehicle-treated cells. Next we assessed the therapeutic potential PDE11Ai’s by determining if they could reverse the increased PDE11A4 LLPS caused by G) the aging-related S117D/S124D mutant,H) staurosporine, or the overexpression of the trans-Golgi network proteins I) TGN-38 (a.k.a. TGOLN1) and J) RhoB. In each experiment, PDE11Ai’s completely blocked the effects of the pro-LLPS manipulations. Post hoc: *vs. vehicle, P=0.0145-0.0001; #vs. WT, mCherry, or 0 µM staurosporine, P=0.0465-0.0001.

    Article Snippet: RFP-tagged Rhob (Cat# RC100059) and RFP-tagged TGOLN/TGN38 plasmids (Cat# RC100061) were obtained from OriGene.

    Techniques: Phospho-proteomics, Mutagenesis, Blocking Assay, Over Expression